Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Cancer stem cells (CSCs) represent a small subset of tumor cells which have the ability to self-renew and generate the diverse cells that comprise the tumor bulk. They are responsible for local tumor recurrence and distant metastasis. However, they are resistant to conventional radiotherapy and chemotherapy. Novel immunotherapeutic strategies that specifically target CSCs may improve the efficacy of cancer therapy. To immunologically target CSC phenotypes, innate immune responses to CSCs have been reported using Natural killer cells and γδ T cells. To target CSC specifically, in vitro CSC-primed T cells have been successfully generated and shown targeting of CSCs in vivo after adoptive transfer. Recently, CSC-based dendritic cell vaccine has demonstrated significant induction of anti-CSC immunity both in vivo in immunocompetent hosts and in vitro as evident by CSC reactivity of CSC vaccine-primed antibodies and T cells. In addition, identification of specific antigens or genetic alterations in CSCs may provide more specific targets for immunotherapy. ALDH, CD44, CD133, and HER2 have served as markers to isolate CSCs from a number of tumor types in animal models and human tumors. They might serve as useful targets for CSC immunotherapy. Finally, since CSCs are regulated by interactions with the CSC niche, these interactions may serve as additional targets for CSC immunotherapy. Targeting the tumor microenvironment, such as interrupting the immune cell, for example, myeloid-derived suppressor cells, and cytokines, for example, IL-6 and IL-8, as well as the immune checkpoint (PD1/PDL1, etc.) may provide additional novel strategies to enhance the immunological targeting of CSCs. Stem Cells 2015;33:2085–2092
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668
Le Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., & Ringdén, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16104-7 · Cited by 2,734
Cancer stem cells: an old idea–a paradigm shift
Wicha, M. S., Liu, S., & Dontu, G. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3153 · Cited by 1,378
Self-citationIliopoulos, D., Hirsch, H. A., & Struhl, K. (2009) · Cell · doi:10.1016/j.cell.2009.10.014 · Cited by 1,374
Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks
Liu, S., Ginestier, C., Ou, S. J., Clouthier, S. G., Patel, S. H., Monville, F., Korkaya, H., Heath, A., Dutcher, J., Kleer, C. G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-0538 · Cited by 611
Self-citationRegulation of mammary stem/progenitor cells by PTEN/Akt/β-catenin signaling
Korkaya, H., Paulson, A., Charafe-Jauffret, E., Ginestier, C., Brown, M., Dutcher, J., Clouthier, S. G., & Wicha, M. S. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000121 · Cited by 523
Self-citationCancer stem cell niche: the place to be
Borovski, T., De Sousa E Melo, F., Vermeulen, L., & Medema, J. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3220 · Cited by 518
Raha, D., Wilson, T. R., Peng, J., Peterson, D., Yue, P., Evangelista, M., Wilson, C., Merchant, M., & Settleman, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3456 · Cited by 307
Cited by
Cancer stem cells—Origins and biomarkers: Perspectives for targeted personalized therapies
Walcher, L., Kistenmacher, A.-K., Suo, H., Kitte, R., Dluczek, S., Strauß, A., Blaudszun, A.-R., Yevsa, T., Fricke, S., & Kossatz-Boehlert, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01280 · Cited by 1,007
Clara, J. A., Monge, C., Yang, Y., & Takebe, N. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0293-2 · Cited by 752
Targeting Cancer Stemness in the Clinic: From Hype to Hope
Saygin, C., Matei, D., Majeti, R., Reizes, O., & Lathia, J. D. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2018.11.017 · Cited by 517
Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance
Chang, J. C. (2016) · Medicine · doi:10.1097/md.0000000000004766 · Cited by 435
Epigenetics in cancer stem cells
Toh, T. B., Lim, J. J., & Chow, E. K.-H. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0596-9 · Cited by 422
Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer
Brooks, M. D., Burness, M. L., & Wicha, M. S. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.08.014 · Cited by 374
Self-citationCarbohydrate-Based Macromolecular Biomaterials
Su, L., Feng, Y., Wei, K., Xu, X., Liu, R., & Chen, G. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01338 · Cited by 335
Therapies targeting cancer stem cells: Current trends and future challenges
Dragu, D. L. (2015) · World Journal of Stem Cells · doi:10.4252/wjsc.v7.i9.1185 · Cited by 257
Ma, J., Zhang, Y., Tang, K., Zhang, H., Yin, X., Li, Y., Xu, P., Sun, Y., Ma, R., Ji, T., et al. (2016) · Cell Research · doi:10.1038/cr.2016.53 · Cited by 253
Ghanbari Movahed, Z., Rastegari-Pouyani, M., Mohammadi, M. H., & Mansouri, K. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108690 · Cited by 208
EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
Zhu, X., Chen, L., Liu, L., & Niu, X. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01044 · Cited by 204
Cancer Stem Cell Plasticity Drives Therapeutic Resistance
Doherty, M., Smigiel, J., Junk, D., & Jackson, M. (2016) · Cancers · doi:10.3390/cancers8010008 · Cited by 160
Ral signaling pathway in health and cancer
Moghadam, A. R., Patrad, E., Tafsiri, E., Peng, W., Fangman, B., Pluard, T. J., Accurso, A., Salacz, M., Shah, K., Ricke, B., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1105 · Cited by 58
CD133-targeted oncolytic adenovirus demonstrates anti-tumor effect in colorectal cancer
Sato-Dahlman, M., Miura, Y., Huang, J. L., Hajeri, P., Jacobsen, K., Davydova, J., & Yamamoto, M. (2017) · Oncotarget · doi:10.18632/oncotarget.18340 · Cited by 43
Metadata
- Authors
- Pan, Q., Li, Q., Liu, S., Ning, N., Zhang, X., Xu, Y., Chang, A. E., & Wicha, M. S.
- Venue
- Stem Cells
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-05-13
- Volume
- 33
- Issue
- 7
- Pages
- 2085-2092
- ISSN
- 1066-5099 (ISSN-L)
- 1549-4918
- OpenAlex
- W1844826649
- Cited by
- 151
- References
- 8
- FWCI
- 7.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.